Diode array detection for stability assessment and evaluation of degradation kinetics of newly introduced sacubitril in its supramolecular complex (LCZ696) with valsartan

Development and validation of a novel stability‐indicating reverse phase HPLC method for the determination of sacubitril–valsartan premix stereoisomers: Cellulose tris(4‐methyl benzoate) stationary phase

“…Few spectrophotometric, liquid chromatographic methods have been reported for the combined determination of related impurities and degradation products (simultaneous quantification of SA and VA from rat plasma; diode array detection for stability assessment and evaluation of degradation kinetics of SA-VA) [8][9][10][11]. A normal phase HPLC method has been reported for the separation of stereoisomers in SA-VA [12].…”

Synchronized determination of sacubitril and valsartan with some co‐administered drugs in human plasma via UPLC–MS/MS method using solid‐phase extraction

“…A literature review revealed that the SAC/VAL combination has been estimated by spectrophotometric (Eissa & Abou Al Alamein, 2018) and spectrofluorimetric methods (Ragab et al, 2017) in their combined tablets. HPLC methods have also been reported for the determination of the binary mixture in bulk powder, pharmaceutical formulations and biological fluids using different detectors such as diode array (Ragab et al, 2018), UV (Naazeen & Sridevi, 2017; Patel et al, 2016; Zhou et al, 2018) and tandem mass (Ayalasomayajula et al, 2015, 2016, 2017; Chunduri & Dannana, 2016; Gan et al, 2016; Gu et al, 2010; Han et al, 2017; Hsiao et al, 2015). However, the aforementioned HPLC–MS/MS methods focus on pharmacokinetic studies (Chunduri & Dannana, 2016; Gu et al, 2010) in rat plasma and the assessment of the drug–drug interaction potential of SAC/VAL with other drugs such as digoxin or warfarin (Ayalasomayajula et al, 2015), hydrochlorothiazide, amlodipine or carvedilol (Hsiao et al, 2015), omeprazole, metformin (Gan et al, 2016) and atorvastatin (Ayalasomayajula et al, 2017).…”